AU2020298092B2 - Process for the preparation of CIC-1 chloride channel inhibitors - Google Patents

Process for the preparation of CIC-1 chloride channel inhibitors

Info

Publication number
AU2020298092B2
AU2020298092B2 AU2020298092A AU2020298092A AU2020298092B2 AU 2020298092 B2 AU2020298092 B2 AU 2020298092B2 AU 2020298092 A AU2020298092 A AU 2020298092A AU 2020298092 A AU2020298092 A AU 2020298092A AU 2020298092 B2 AU2020298092 B2 AU 2020298092B2
Authority
AU
Australia
Prior art keywords
phenoxy
dihydroisoxazol
bromo
butoxy
propanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020298092A
Other languages
English (en)
Other versions
AU2020298092A1 (en
AU2020298092A8 (en
Inventor
Nicholas Kelly
Michael John Mckenzie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NMD Pharma AS
Original Assignee
NMD Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NMD Pharma AS filed Critical NMD Pharma AS
Publication of AU2020298092A1 publication Critical patent/AU2020298092A1/en
Publication of AU2020298092A8 publication Critical patent/AU2020298092A8/en
Application granted granted Critical
Publication of AU2020298092B2 publication Critical patent/AU2020298092B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2020298092A 2019-06-19 2020-06-19 Process for the preparation of CIC-1 chloride channel inhibitors Active AU2020298092B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19181262 2019-06-19
EP19181262.7 2019-06-19
PCT/EP2020/067065 WO2020254554A1 (en) 2019-06-19 2020-06-19 Process for the preparation of clc-1 chloride channel inhibitors

Publications (3)

Publication Number Publication Date
AU2020298092A1 AU2020298092A1 (en) 2021-11-18
AU2020298092A8 AU2020298092A8 (en) 2025-04-24
AU2020298092B2 true AU2020298092B2 (en) 2025-09-25

Family

ID=66999603

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020298092A Active AU2020298092B2 (en) 2019-06-19 2020-06-19 Process for the preparation of CIC-1 chloride channel inhibitors

Country Status (18)

Country Link
US (1) US12221425B2 (https=)
EP (1) EP3986878B1 (https=)
JP (1) JP7595945B2 (https=)
KR (1) KR102900834B1 (https=)
CN (1) CN113993852B (https=)
AR (1) AR119198A1 (https=)
AU (1) AU2020298092B2 (https=)
BR (1) BR112021025588A2 (https=)
CA (1) CA3137672A1 (https=)
ES (1) ES3000437T3 (https=)
HU (1) HUE069104T2 (https=)
IL (1) IL287901B2 (https=)
MX (1) MX2021013507A (https=)
PL (1) PL3986878T3 (https=)
SG (1) SG11202111122RA (https=)
TW (1) TWI849152B (https=)
WO (1) WO2020254554A1 (https=)
ZA (1) ZA202107653B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4593829A1 (en) 2022-09-30 2025-08-06 NMD Pharma A/S Compositions and methods for treating myasthenia gravis
WO2024180199A1 (en) 2023-03-02 2024-09-06 Nmd Pharma A/S Compositions and methods for treating charcot–marie–tooth disease
JP2026508357A (ja) 2023-03-02 2026-03-10 エヌエムディー ファーマ エー／エス 脊髄性筋萎縮症を処置するための組成物及び方法
EP4731200A1 (en) 2023-06-20 2026-04-29 NMD Pharma A/S Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019115781A1 (en) * 2017-12-14 2019-06-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
GB0524428D0 (en) * 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
WO2009097970A1 (de) * 2008-02-05 2009-08-13 Sanofi-Aventis Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
JP2015505560A (ja) * 2012-02-03 2015-02-23 ゾエティス・エルエルシー 抗寄生虫薬としてのキラルイソオキサゾリンアゼチジン誘導体の製造法
MX389242B (es) 2015-06-15 2025-03-20 Nmd Pharma As Compuestos para su uso en el tratamiento de trastornos neuromusculares
US10385028B2 (en) * 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019115781A1 (en) * 2017-12-14 2019-06-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARCHIV DER PHARMAZIE,, 1961, vol. 294, no. 12, pages 769 - 774. *
BULL. CHEM. SOC. JPN., 1990, vol. 63, pages 2739-2741. *
JOURNAL OF THE INDIAN CHEMICAL SOCIETY, 1984, vol. 61, pages 604 - 606. *

Also Published As

Publication number Publication date
EP3986878A1 (en) 2022-04-27
HUE069104T2 (hu) 2025-02-28
BR112021025588A2 (pt) 2022-02-01
IL287901A (en) 2022-01-01
PL3986878T3 (pl) 2025-01-20
EP3986878C0 (en) 2024-09-25
CN113993852A (zh) 2022-01-28
TWI849152B (zh) 2024-07-21
US12221425B2 (en) 2025-02-11
KR102900834B1 (ko) 2025-12-16
AU2020298092A1 (en) 2021-11-18
CN113993852B (zh) 2024-12-17
SG11202111122RA (en) 2021-11-29
MX2021013507A (es) 2021-12-10
TW202115003A (zh) 2021-04-16
AU2020298092A8 (en) 2025-04-24
IL287901B2 (en) 2025-02-01
CA3137672A1 (en) 2020-12-24
WO2020254554A1 (en) 2020-12-24
ES3000437T3 (en) 2025-02-28
JP2022537493A (ja) 2022-08-26
JP7595945B2 (ja) 2024-12-09
IL287901B1 (en) 2024-10-01
ZA202107653B (en) 2023-05-31
EP3986878B1 (en) 2024-09-25
KR20220022895A (ko) 2022-02-28
AR119198A1 (es) 2021-12-01
US20220298124A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
AU2020298092B2 (en) Process for the preparation of CIC-1 chloride channel inhibitors
TWI345562B (en) Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
CA3164134A1 (en) Substituted tetrahydrofurans as modulators of sodium channels
US5387595A (en) Alicyclic compounds as tachykinin receptor antagonists
EP3237379B1 (en) Process for preparing alpha-carboxamide pyrrolidine derivatives
TW202304864A (zh) 1,3-取代的環丁基衍生物及其用途
TWI771827B (zh) 製造６－羧基苯並㗁唑衍生物之有效方法
HK40068865B (en) Process for the preparation of clc-1 chloride channel inhibitors
HK40068865A (en) Process for the preparation of clc-1 chloride channel inhibitors
TW201124383A (en) Process for preparing biphenyl imidazole compounds
Kruse et al. Decarbethoxylation and ring-opening reactions of 2-tetrahydrofuranyl-, 2-tetrahydrothienyl-, and 2-(1, 3-dithianyl)-substituted esters
US11578081B1 (en) Crystal form as inhibitor of ACC1 and ACC2, and preparation method therefor and use thereof
EP3939976B1 (en) Prodrug of caspase inhibitor
US9920045B2 (en) Solid state forms of a PDE10 inhibitor
Kolasa et al. Esters of N‐Benzyloxyamino Acids
JP7198968B2 (ja) チエノ［２，３－ｃ］ピリダジン－４（１Ｈ）－オン系化合物の結晶形及びその製造方法並びに使用
US4009179A (en) Di- and tri-substituted oxazolidin-2-one oximes
WO2018033631A9 (en) Morphic forms of marizomib and uses thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 35 , NO 46 , PAGE(S) 9040 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME NMD PHARMA A/S, APPLICATION NO. 2020298092, UNDER INID (54) CORRECT THE TITLE TO READ PROCESS FOR THE PREPARATION OF CIC-1 CHLORIDE CHANNEL INHIBITORS

FGA Letters patent sealed or granted (standard patent)